NCT05080556
- Conditions
- Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
- Locations
-
- University College London Hospitals London, United Kingdom
Clinical trial condition
Relapsed Ovarian Cancer
Explore clinical trials studying Relapsed Ovarian Cancer. Study availability and eligibility vary by location and protocol.
9 public trials
2 recruiting studies
Relapsed Ovarian Cancer trial results
NCT05607329
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
- Women's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China
Not Yet Recruiting
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
NCT06081595
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
Not specified
Not Yet Recruiting
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
NCT05479487
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
Not specified
NCT03534453
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
- Locations
-
- Research Site Beijing, China
- Research Site Changsha, China
- Research Site Chengdu, China
- Research Site Chongqing, China
NCT04517357
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
- Zhejiang Cancer Hospital Hangzhou, Zhejiang, China
NCT02825420
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
- Locations
-
- O.L.V. Aalst Aalst, Flanders, Belgium
- AZ Maria Middelares Ghent, Flanders, Belgium
- Centre Hospitalier de Jolimont La Louvière, Henao, Belgium
- CHU Ambroise-Paré Mons, Henao, Belgium
Active, Not Recruiting
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353
- Conditions
- Adnexal Diseases, BRCA Mutated, Endocrine Gland Neoplasms, +16 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Palo Alto Foundation Medical Group San Francisco, California, United States
- University of Colorado Aurora, Colorado, United States
- The Hospital of Central Connecticut New Britain, Connecticut, United States
Active, Not Recruiting
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514
- Conditions
- Adnexal Diseases, Disease Attributes, Endocrine Gland Neoplasms, +18 more
- Locations
-
- UZ Leuven Leuven, Belgium
- Centre Hospitalier de l'Ardenne Vivalia Libramont, Belgium
- Centre Hospitalier Universitaire de Liège Liège, Belgium
- ICO Paul Papin Angers, France